• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    CMCT Announces 30,821-Square-Foot Lease to Boston Scientific Corporation at Penn Field, a 228,000-Square-Foot Creative Office Campus in Austin

    8/5/25 8:00:00 AM ET
    $BSX
    $CMCT
    Medical/Dental Instruments
    Health Care
    Real Estate Investment Trusts
    Real Estate
    Get the next $BSX alert in real time by email

    Transaction Brings Property to 93% Leased

    Creative Media and Community Trust Corporation ("CMCT") (NASDAQ:CMCT) announced today that it has executed an approximately 11-year lease with Boston Scientific Corporation (NYSE:BSX) for an entire 30,821-square-foot, one-story building at its Penn Field Campus located at 3601 S. Congress Avenue in Austin, Texas.

    Boston Scientific is a global medical technology leader that provides a broad range of high-performance solutions that address unmet patient needs and reduces the cost of healthcare. The company's devices and therapies help physicians diagnose and treat complex cardiovascular, respiratory, digestive, oncological, neurological and urological diseases and conditions.

    Penn Field, an approximately 228,000-square-foot, 16-acre, mixed-use property located in Austin's "SoCo" Business District, was originally developed in 1918 as an air base for the U.S. Army. The industrial buildings of post-World War I design have been transformed over time into what is today, a lushly landscaped campus with meandering pathways shaded by mature trees. The property has a diverse tenant base including technology, media, and entertainment companies.

    AQUILA Commercial, in partnership with CIM Group's in-house leasing team, represented CMCT in the transaction. Penn Field is now 93% leased as of August 2025.

    ABOUT CMCT

    Creative Media & Community Trust Corporation ("CMCT") is a real estate investment trust that owns, operates and develops premier multifamily and creative office assets in vibrant communities throughout the United States. CMCT is a leader in creative office, acquiring and developing properties catering to rapidly growing industries such as technology, media and entertainment. CMCT applies the expertise of CIM Group, L.P. to the acquisition, development, and operation of top-tier multifamily properties situated in dynamic markets with similar business and employment characteristics to its creative office investments. CMCT also owns one hotel in Northern California and a lending platform that originates loans under the Small Business Administration's 7(a) loan program. CMCT is operated by affiliates of CIM Group, L.P., a vertically integrated owner and operator of real assets with multi-disciplinary expertise and in-house research, acquisition, credit analysis, development, finance, leasing, and onsite property management capabilities. (www.creativemediacommunity.com)

    Forward Looking Statements

    This press release contains certain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), which are intended to be covered by the safe harbors created thereby. These statements include the plans and objectives of management for future operations, including plans and objectives relating to future growth of CMCT's business and availability of funds. Such forward-looking statements can be identified by the use of forward-looking terminology such as "may," "will," "project," "target," "expect," "intend," "might," "believe," "anticipate," "estimate," "could," "would," "continue," "pursue," "potential," "forecast," "seek," "plan," or "should," or "goal" or the negative thereof or other variations or similar words or phrases. Such forward-looking statements also include, among others, statements about CMCT's plans and objectives relating to future growth and outlook. Such forward-looking statements are based on particular assumptions that management of CMCT has made in light of its experience, as well as its perception of expected future developments and other factors that it believes are appropriate under the circumstances. Forward-looking statements are necessarily estimates reflecting the judgment of CMCT's management and involve a number of risks and uncertainties that could cause actual results to differ materially from those suggested by the forward-looking statements. These risks and uncertainties include those associated with (i) the timing, form, and operational effects of CMCT's development activities, (ii) the ability of CMCT to raise in place rents to existing market rents and to maintain or increase occupancy levels, (iii) fluctuations in market rents, (iv) the effects of inflation and continuing higher interest rates on the operations and profitability of CMCT and (v) general economic, market and other conditions. Additional important factors that could cause CMCT's actual results to differ materially from CMCT's expectations are discussed in "Item 1A—Risk Factors" in CMCT's Annual Report on Form 10-K for the year ended December 31, 2024 and in Part II, Item 1A of CMCT's Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission from time to time. The forward-looking statements included herein are based on current expectations and there can be no assurance that these expectations will be attained. Assumptions relating to the foregoing involve judgments with respect to, among other things, future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond CMCT's control. Although we believe that the assumptions underlying the forward-looking statements are reasonable, any of the assumptions could be inaccurate and, therefore, there can be no assurance that the forward-looking statements expressed or implied will prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statements expressed or implied herein, the inclusion of such information should not be regarded as a representation by CMCT or any other person that CMCT's objectives and plans will be achieved. Readers are cautioned not to place undue reliance on forward-looking statements. Forward-looking statements speak only as of the date they are made. CMCT does not undertake to update them to reflect changes that occur after the date they are made, except as may be required by applicable laws.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250805520412/en/

    For CIM Commercial Trust Corporation

    Media Relations:

    Karen Diehl, Diehl Communications, 310-741-9097

    [email protected]

    or

    Shareholder Relations:

    Steve Altebrando, 646-652-8473

    [email protected]

    Get the next $BSX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BSX
    $CMCT

    CompanyDatePrice TargetRatingAnalyst
    Boston Scientific Corporation
    $BSX
    3/30/2026$88.00Strong Buy → Outperform
    Raymond James
    Boston Scientific Corporation
    $BSX
    10/3/2025Buy → Hold
    Erste Group
    Boston Scientific Corporation
    $BSX
    9/8/2025$125.00Perform → Outperform
    Oppenheimer
    Boston Scientific Corporation
    $BSX
    6/16/2025$118.00Outperform
    Leerink Partners
    Boston Scientific Corporation
    $BSX
    4/16/2025$113.00Hold → Buy
    Needham
    Boston Scientific Corporation
    $BSX
    1/10/2025$108.00Hold → Buy
    Deutsche Bank
    Boston Scientific Corporation
    $BSX
    10/18/2024Buy → Hold
    Needham
    Boston Scientific Corporation
    $BSX
    5/30/2024$90.00Buy
    Goldman
    More analyst ratings

    $BSX
    $CMCT
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    March 1, 2024 - FDA Roundup: March 1, 2024

    For Immediate Release: March 01, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA issued a letter of enforcement discretion for certain qualified health claims regarding the consumption of yogurt and the reduced risk of type 2 diabetes. The letter states that the FDA does not intend to object to the use of these claims, provide

    3/1/24 4:00:21 PM ET
    $BSX
    Medical/Dental Instruments
    Health Care

    $BSX
    $CMCT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Ressler Richard S

    4 - Creative Media & Community Trust Corp (0000908311) (Issuer)

    3/18/26 6:15:26 PM ET
    $CMCT
    Real Estate Investment Trusts
    Real Estate

    SEC Form 4 filed by Kuba Shaul

    4 - Creative Media & Community Trust Corp (0000908311) (Issuer)

    3/18/26 6:14:52 PM ET
    $CMCT
    Real Estate Investment Trusts
    Real Estate

    SEC Form 4 filed by Shemesh Avraham

    4 - Creative Media & Community Trust Corp (0000908311) (Issuer)

    3/18/26 6:14:40 PM ET
    $CMCT
    Real Estate Investment Trusts
    Real Estate

    $BSX
    $CMCT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Boston Scientific downgraded by Raymond James with a new price target

    Raymond James downgraded Boston Scientific from Strong Buy to Outperform and set a new price target of $88.00

    3/30/26 8:15:23 AM ET
    $BSX
    Medical/Dental Instruments
    Health Care

    Boston Scientific downgraded by Erste Group

    Erste Group downgraded Boston Scientific from Buy to Hold

    10/3/25 8:32:04 AM ET
    $BSX
    Medical/Dental Instruments
    Health Care

    Boston Scientific upgraded by Oppenheimer with a new price target

    Oppenheimer upgraded Boston Scientific from Perform to Outperform and set a new price target of $125.00

    9/8/25 8:36:41 AM ET
    $BSX
    Medical/Dental Instruments
    Health Care

    $BSX
    $CMCT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    $BSX
    $CMCT
    SEC Filings

    View All

    $BSX
    $CMCT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Boston Scientific announces conference call discussing first quarter 2026 results

    MARLBOROUGH, Mass., March 30, 2026 /PRNewswire/ -- Boston Scientific Corporation (NYSE:BSX) will webcast its conference call discussing financial results and business highlights for the first quarter ended March 31, 2026, on Wednesday, April 22, 2026, at 8:00 a.m. ET. The call will be hosted by Mike Mahoney, chairman and chief executive officer, and Jon Monson, executive vice president and chief financial officer. The company will issue a news release announcing financial results for the first quarter on April 22 prior to the conference call. A live webcast and replay for the ev

    3/30/26 8:00:00 AM ET
    $BSX
    Medical/Dental Instruments
    Health Care

    CHAMPION-AF study of the WATCHMAN FLX™ Left Atrial Appendage Closure Device as a first-line therapy for stroke risk reduction meets all primary and secondary safety and efficacy endpoints

    Data highlights the WATCHMAN FLX device provided statistically superior protection from bleeding, demonstrated similar efficacy compared to blood thinners in patients with non-valvular atrial fibrillation Late-breaking findings presented at ACC.26 and simultaneously published in The New England Journal of MedicineMARLBOROUGH, Mass. and NEW ORLEANS, March 28, 2026 /PRNewswire/ -- Boston Scientific Corporation (NYSE:BSX) today announced that the CHAMPION-AF global clinical trial met all primary and secondary safety and efficacy endpoints. The study evaluated the WATCHMAN FLX™ Left Atrial Appendage Closure (LAAC) Device compared to non-vitamin K antagonist oral anticoagulants (NOACs) as a first

    3/28/26 10:55:00 AM ET
    $BSX
    Medical/Dental Instruments
    Health Care

    HI-PEITHO trial demonstrates Boston Scientific EKOS™ Endovascular System is superior to standard of care for treatment of acute pulmonary embolism

    Global randomized trial demonstrated statistically significant reduction in clinical event rates in patients with intermediate-risk PE when treated with the EKOS device plus anticoagulation vs. anticoagulation aloneLate breaking findings presented at ACC.26 and simultaneously published in The New England Journal of MedicineMARLBOROUGH, Mass. and NEW ORLEANS, March 28, 2026 /PRNewswire/ -- Boston Scientific Corporation (NYSE:BSX) today announced positive data from the HI-PEITHO global randomized clinical trial evaluating the use of the EKOS™ Endovascular System in patients with intermediate-risk pulmonary embolism (PE). The study met the composite primary endpoint, with data demonstrating tha

    3/28/26 10:38:00 AM ET
    $BSX
    Medical/Dental Instruments
    Health Care

    SEC Form EFFECT filed by Boston Scientific Corporation

    EFFECT - BOSTON SCIENTIFIC CORP (0000885725) (Filer)

    4/2/26 12:15:23 AM ET
    $BSX
    Medical/Dental Instruments
    Health Care

    SEC Form 424B3 filed by Boston Scientific Corporation

    424B3 - BOSTON SCIENTIFIC CORP (0000885725) (Filer)

    4/1/26 4:30:44 PM ET
    $BSX
    Medical/Dental Instruments
    Health Care

    Creative Media & Community Trust Corporation filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

    8-K - Creative Media & Community Trust Corp (0000908311) (Filer)

    3/31/26 4:03:06 PM ET
    $CMCT
    Real Estate Investment Trusts
    Real Estate

    EVP & Group Pres, Cardiology Fitzgerald Joseph Michael bought $4,515 worth of shares (50 units at $90.29), sold $1,799 worth of shares (20 units at $89.97), was granted 31,680 shares and covered exercise/tax liability with 14,447 shares, increasing direct ownership by 17% to 172,863 units (SEC Form 4)

    4 - BOSTON SCIENTIFIC CORP (0000885725) (Issuer)

    2/13/25 4:32:41 PM ET
    $BSX
    Medical/Dental Instruments
    Health Care

    $BSX
    $CMCT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Creative Media & Community Trust Corporation

    SC 13D/A - Creative Media & Community Trust Corp (0000908311) (Subject)

    9/27/24 4:26:04 PM ET
    $CMCT
    Real Estate Investment Trusts
    Real Estate

    SEC Form SC 13D/A filed by Creative Media & Community Trust Corporation (Amendment)

    SC 13D/A - Creative Media & Community Trust Corp (0000908311) (Subject)

    4/15/24 5:16:18 PM ET
    $CMCT
    Real Estate Investment Trusts
    Real Estate

    SEC Form SC 13G/A filed by Boston Scientific Corporation (Amendment)

    SC 13G/A - BOSTON SCIENTIFIC CORP (0000885725) (Subject)

    2/13/24 5:00:46 PM ET
    $BSX
    Medical/Dental Instruments
    Health Care

    $BSX
    $CMCT
    Leadership Updates

    Live Leadership Updates

    View All

    CathVision Announces Appointment of Eric Thepaut as Independent Chairman of the Board and Releases ECGenius® System Version 3.5

    COPENHAGEN, Denmark, Dec. 10, 2025 /PRNewswire/ -- CathVision, a medical technology company dedicated to improving clinical outcomes in cardiac electrophysiology through high-fidelity signal acquisition and intelligent software, today announced two major milestones: the appointment of Eric Thepaut as independent Chairman of the Board, and the commercial release of Version 3.5 of the ECGenius® System. Eric Thepaut Appointed Independent Chairman of the Board Eric Thepaut joins CathVision following his recent retirement from Boston Scientific Corporation (NYSE:BSX), where he serv

    12/10/25 4:00:00 AM ET
    $BSX
    Medical/Dental Instruments
    Health Care

    Archimedes Vascular Announces Close of Series A Financing led by Sherpa Healthcare Partners and Appoints Raymond W. Cohen as Chairman of its Board of Directors

    BIRMINGHAM, Ala. and BEIJING, June 23, 2025 /PRNewswire/ -- Archimedes Vascular, Inc., a pre-clinical stage medical device company developing an implant for the treatment of severe hypertension announced a $2.2 million Series A financing led by Sherpa Healthcare Partners. In conjunction with the financing, also announced the appointment of veteran medical device executive, Raymond W. Cohen to serve as chairman of its board of directors. "We are grateful to Sherpa and Ray for recognizing the potential of this exciting project and providing the funding to facilitate execution of

    6/23/25 9:00:00 AM ET
    $BSX
    $KMTS
    Medical/Dental Instruments
    Health Care

    Nalu Medical Appoints Veteran Medtech Executive Raymond W. Cohen Chairman of its Board of Directors

    Nalu Medical, Inc. ("Nalu") announced today the appointment of Raymond W. Cohen to serve as chairman of its board of directors. Raymond Cohen served as the chief executive officer and member of the board of directors of Nasdaq-listed Axonics, Inc., a medical device company he co-founded in 2013 and took public in late October 2018. Axonics ranked No. 1 on the Deloitte Technology Fast 500™ and the Financial Times ranking of the fastest growing companies in the Americas in 2021 and 2022. Cohen retired from Axonics following the November 2024 close of its $3.7 billion sale to Boston Scientific Corporation (NYSE:BSX). Following the sale of Axonics, Cohen was named chairman of the board of Son

    4/3/25 11:00:00 AM ET
    $BSX
    $KMTS
    Medical/Dental Instruments
    Health Care

    $BSX
    $CMCT
    Financials

    Live finance-specific insights

    View All

    Boston Scientific announces conference call discussing first quarter 2026 results

    MARLBOROUGH, Mass., March 30, 2026 /PRNewswire/ -- Boston Scientific Corporation (NYSE:BSX) will webcast its conference call discussing financial results and business highlights for the first quarter ended March 31, 2026, on Wednesday, April 22, 2026, at 8:00 a.m. ET. The call will be hosted by Mike Mahoney, chairman and chief executive officer, and Jon Monson, executive vice president and chief financial officer. The company will issue a news release announcing financial results for the first quarter on April 22 prior to the conference call. A live webcast and replay for the ev

    3/30/26 8:00:00 AM ET
    $BSX
    Medical/Dental Instruments
    Health Care

    CMCT Declares Preferred Stock Dividends

    Creative Media & Community Trust Corporation (NASDAQ:CMCT) (the "Company") announced today that its Board of Directors has declared preferred stock dividends on its Series A, Series A1 and Series D Preferred Stock for the first quarter of 2026. The dividend will be payable on April 15, 2026 to holders of record on April 5, 2026. The dividend amounts are as follows:   Quarterly Dividend Amount Series A Preferred Stock $0.34375 per share Series A1 Preferred Stock $0.399375 per share* Series D Preferred Stock $0.353125 per share *The quarterly cash dividend of $0.399375 per share represents an annualized dividend rate of 6.39% (2.5%

    3/27/26 8:00:00 AM ET
    $CMCT
    Real Estate Investment Trusts
    Real Estate

    CMCT Announces Completion of Preferred Stock Redemption

    Creative Media & Community Trust Corporation (NASDAQ:CMCT) ("we", "our", "CMCT", or the "Company") announced today that it has redeemed approximately 1,957,823 shares of Series A Preferred Stock, par value $0.001 per share, approximately 7,734,130 shares of Series A1 Preferred Stock, par value $0.001 per share, and approximately 21,760 shares of Series D Preferred Stock, par value $0.001 per share (collectively, the "Preferred Stock"), in shares of Common Stock (the "March 2026 Redemption"). The redemption improves the Company's Funds from Operations attributable to common stockholders ("FFO")1 and balance sheet and positions shareholders to benefit from improving operating trends across

    3/16/26 8:00:00 AM ET
    $CMCT
    Real Estate Investment Trusts
    Real Estate